Findings show lingdolinurad, a novel orally administered URAT1 inhibitor, achieved its primary endpoint in lowering uric acid and demonstrated good safety and tolerability Atom Therapeutics Co., Ltd, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback